Penumbra, Inc. (NYSE:PEN) Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its position in Penumbra, Inc. (NYSE:PEN) by 1.0% in the fourth quarter, Holdings Channel reports. The firm owned 8,476 shares of the company’s stock after selling 87 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Penumbra were worth $2,013,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its stake in Penumbra by 128.1% in the third quarter. Janus Henderson Group PLC now owns 668,873 shares of the company’s stock valued at $129,967,000 after buying an additional 375,684 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in shares of Penumbra in the 3rd quarter valued at $31,965,000. Braidwell LP raised its position in Penumbra by 70.0% in the 3rd quarter. Braidwell LP now owns 361,428 shares of the company’s stock valued at $70,229,000 after purchasing an additional 148,834 shares during the last quarter. Baillie Gifford & Co. boosted its stake in Penumbra by 23.4% during the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company’s stock worth $173,416,000 after purchasing an additional 138,387 shares during the period. Finally, FMR LLC grew its position in Penumbra by 2.1% during the 3rd quarter. FMR LLC now owns 5,896,396 shares of the company’s stock worth $1,145,729,000 after purchasing an additional 121,465 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra Trading Up 2.0 %

Shares of PEN opened at $286.09 on Tuesday. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $11.02 billion, a P/E ratio of 841.45, a PEG ratio of 2.83 and a beta of 0.51. The firm’s 50-day moving average is $273.48 and its two-hundred day moving average is $241.14.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. The firm had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. On average, research analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Insider Transactions at Penumbra

In related news, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the completion of the transaction, the director now directly owns 8,530 shares in the company, valued at $2,058,118.40. The trade was a 1.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Adam Elsesser sold 16,600 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $276.21, for a total value of $4,585,086.00. Following the completion of the sale, the chief executive officer now directly owns 27,752 shares in the company, valued at approximately $7,665,379.92. The trade was a 37.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,518 shares of company stock valued at $22,994,979 in the last 90 days. 5.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Oppenheimer started coverage on Penumbra in a research report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 price objective for the company. Morgan Stanley boosted their target price on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, February 19th. Canaccord Genuity Group increased their price target on Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Royal Bank of Canada lifted their price objective on shares of Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Penumbra presently has an average rating of “Moderate Buy” and an average price target of $294.47.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.